ClinicalTrials.gg
Not yet recruitingNCT07897318TUPISUpdated Oct 27, 2026

Mi2000 TICI - Post-market Implantation Study

An interventional study of Cochlear Implantation in Hearing Loss, Binaural and Cochlear Implantation, sponsored by MED-EL Elektromedizinische Geräte GmbH. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-27.

Sponsored by MED-EL Elektromedizinische Geräte GmbH · Not applicable, Interventional, and Treatment

Updated Oct 27, 2026Newly registeredGo to Updates ↓
Phase
Not applicable
Study type
Interventional
Enrollment
22
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This Post-Market Clinical Follow-up (PMCF) investigation aims to further collect evidence on safety and performance of the Mi2000 TICI. This PMCF investigation will prospectively collect clinical data from the use of the Mi2000 TICI and related devices.

This PMCF investigation is performed on a cochlear implant system newly introduced to the market, which was previously studied in two pre-market clinical investigations. The purpose of the current clinical investigation is to collect further evidence by collecting additional clinical data on the use of the Mi2000 TICI.

02

Conditions studied

  • Hearing Loss, Binaural
  • Cochlear Implantation

Browse trials for

Keywords

  • Cochlear Implant
  • Totally Implantable Cochlear Implant
  • TICI
  • Fully Implantable Cochlear Implant
03

In context

Hearing Loss

796 studies on the registry are indexed under Hearing Loss; 193 are open to participants now.

This study's planned enrollment of 22 is below the median of 44 across 561 interventional studies indexed under Hearing Loss.

Browse Hearing Loss studies →

Lead sponsor

MED-EL Elektromedizinische Geräte GmbH is the lead sponsor of 4 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Minimum age of eighteen (18) years at time of enrolment
  • Bilateral sensorineural hearing loss with no or limited benefit from a hearing aid (>70 dB HL PTA4(500, 1000, 2000, 4000Hz))
  • Post-lingual onset of deafness
  • No or limited benefit from hearing aids for less than 10 years and an expected benefit from cochlear implantation
  • A maximum score of 50% on a word test in the language of the test center in the ear to be implanted in the best aided condition
  • Fluency in the test language with excellent proficiency, as appropriate to perform speech testing
  • Functional auditory nerve
  • General health condition, psychological and emotional condition deemed compatible with the treatment and tests performed in this study
  • Pre-operative assessment according to the local professional standards
  • Candidate is highly motivated and has realistic expectations about the expected benefit of the implant and shall understand the importance of returning to the implant center for regular speech processor programming, assessment sessions and training
  • Realistic expectations, as deemed appropriate by the implanting surgeon/implant board
  • Signed and dated before the start of any study-specific procedure

Exclusion criteria

Exclusion Criteria:

  • Lack of compliance with any inclusion criterion
  • Previously having received an implant on the location chosen for placing the cochlear implant
  • Having received a hearing implant from another manufacturer than MED-EL on the contralateral ear
  • Pre-existing condition known to necessitate MRI scans after implantation of the Mi2000 TICI
  • Women being pregnant or nursing
  • The individual is known to be intolerant of the materials used in the implant or other required accessories
  • Absence of cochlear development
  • The cause of deafness is non-functionality of the auditory nerve and/or the upper auditory pathway
  • Medical to middle ear and/or inner ear surgery, and/or anesthesia
  • External or middle ear infections are present
  • The tympanic membrane is perforated in the ear to be implanted
  • Anatomic abnormalities are present that would prevent appropriate placement of the stimulator housing in the bone of the skull, or prevent placement of the chosen electrode array into the cochlea (including ossification of the cochlea)
  • The psychological status of the individual is unstable
  • The individual has unrealistic expectations
  • Acute cholesteatoma
  • History of vestibular schwannoma
  • Unstable Meniere's disease
  • Auditory Neuropathy
  • Epilepsy not responding to treatment
  • Permanent inability and/or unwillingness to participation in post-operative care and rehabilitation
  • Known intellectual disability and/or psychological diseases
  • Participation in other pharmacological clinical trials within four weeks prior to enrolment
  • Anything that, in the opinion of the Investigator, would

    • place the subject at increased risk
    • preclude the subject's full compliance with or completion of the study
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
22 participants (estimated)

Study arms

  • Experimental
    TICI recipients

    Participants in this clinical investigation will be implanted with an Mi2000 TICI totally cochlear implant

    Device: Cochlear Implantation

Interventions

  • DeviceCochlear Implantation

    Participants in this clinical investigation will receive a totally implantable cochlear implant.

06

What researchers measure

Primary outcomes

  1. Word Test in Quiet

    Word recognition in quiet, on a scale from 0 to 100% correct, higher scores indicate better outcomes

    Time frame: Pre-op to 6 months after first fitting

  2. Sentence Test in Noise

    Oldenburg Matrix Test, results measured in dB signal-to-noise ratio (SNR) with a range of +30 to -10 dB SNR, lower values indicating better outcomes

    Time frame: Pre-op to 6 months after first fitting

Secondary outcomes

  1. Health Utility Index Mark 3 (HUI3)

    Health utility scale: 1.00: Perfect health. 0.00: Death. Negative values: States worse than death.

    Time frame: Pre-op to 6 months after first fitting

  2. Nijmegen Cochlear Implant Questionnaire (NCIQ)

    Disease specific Quality of Life, overall score is on a scale from 0 to 100, higher numbers indicating better outcomes

    Time frame: Pre-op to 6 months after first fitting

  3. Change in body sound perception

    Participant reported scale on body sound perception (0 - no disturbance to 10 - very disturbing)

    Time frame: through study completion, an average of 12 months after first fitting

  4. Change in stigma perception

    Participant reported scale on stigma perception (0 - no stigmatization to 10 - strong stigmatization)

    Time frame: through study completion, an average of 12 months after first fitting

  5. Change in comfort perception

    Participant reported scale on stigma perception (0 - not comfortable to 10 - very comfortable)

    Time frame: through study completion, an average of 12 months after first fitting

Other outcomes

  1. Word test in quiet

    Word recognition in quiet, on a scale from 0 to 100% correct, higher scores indicate better outcomes

    Time frame: through study completion, an average of 12 months after first fitting

  2. Sentence Test in Noise

    Oldenburg Matrix Test, results measured in dB signal-to-noise ratio (SNR) with a range of +30 to -10 dB SNR, lower values indicating better outcomes

    Time frame: through study completion, an average of 12 months after first fitting

  3. Health Utility Index Mark 3 (HUI3)

    Health utility scale: 1.00: Perfect health. 0.00: Death. Negative values: States worse than death.

    Time frame: through study completion, an average of 12 months after first fitting

  4. Nijmegen Cochlear Implant Questionnaire (NCIQ)

    Disease specific Quality of Life, overall score is on a scale from 0 to 100, higher numbers indicating better outcomes

    Time frame: through study completion, an average of 12 months after first fitting

  5. Speech, Spatial, Quality of Hearing (SSQ12)

    Speech, Spatial and Quality of hearing scale from 0 to 10, higher numbers indicating better outcomes

    Time frame: through study completion, an average of 12 months after first fitting

  6. Hearing Implant Sound Quality Index (HISQUI)

    Sound quality score ranging from 19 (very poor sound quality) to 133 (very good sound quality)

    Time frame: through study completion, an average of 12 months after first fitting

  7. Tinnitus Functional Index (TFI)

    Tinnitus questionnaire measures the severity and negative impact of tinnitus on a 0 (Not a Problem / Slight Tinnitus) to 100 (Very Big Problem / Very Severe Tinnitus) scale

    Time frame: through study completion, an average of 12 months after first fitting

  8. Audiogram

    Pure-tone air-conduction hearing thresholds will be measured in each ear. The threshold is the lowest sound level, in decibels hearing level (dB HL), at which the participant responds. The outcome is the threshold at each frequency. Higher thresholds mean poorer hearing; lower thresholds better hearing.

    Time frame: through study completion, an average of 12 months after first fitting

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

1 registry update since Sep 25, 2026
Registered
First appeared on the registry. No changes since
Oct 27, 2026
Show all 1 update
  1. Oct 27, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07897318
Lead sponsor
MED-EL Elektromedizinische Geräte GmbH
Responsible party
Sponsor
First posted
Oct 27, 2026
Start date
Oct 2026 (estimated)
Primary completion
Dec 2028 (estimated)
Completion
Dec 2028 (estimated)
Last update
Oct 27, 2026

Study contacts

Florian Schwarze, PhD
Contact
studies@medel.com
+4357788
Florian Schwarze
study director · MED-EL

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion